CRISPR therapy targets Hard-to-Treat lung cancer in liver
NCT ID NCT07461727
First seen Mar 22, 2026 · Last updated Jun 23, 2026 · Updated 24 times
Summary
This early-phase trial is testing a new gene-editing drug called EDB-102 for people with advanced non-small cell lung cancer that has spread to the liver and no longer responds to standard targeted therapies. The drug uses CRISPR technology to try to disable a specific cancer-driving gene. The study will enroll 15 participants and focus on safety, while also looking at whether the treatment shrinks tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
EDB-102 (a CRISPR-Cas9 gene-editing therapy delivered via lipid nanoparticles)
What this could lead to
If successful, this could point toward a new treatment option for patients with a specific type of lung cancer that has spread to the liver and stopped responding to current drugs.
What could go wrong
This is a very early, small Phase 1 trial with only 15 participants, so it is primarily testing safety. The gene-editing approach is novel and may not work as hoped, and there are risks of infusion reactions or other side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.